Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crocs, Inc. - Common Stock (NQ:CROX)

83.75 -1.40 (-1.64%)
Streaming Delayed Price Updated: 11:24 AM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crocs, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
36 37 Next >
This Top Shoe Stock Made More Money Than Ever in 2023. Here's Why That's Good for Investors in 2024 and Beyond.
Management has options to reward shareholders for years to come. 
Via The Motley Fool
10 Consumer Discretionary Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Is This 1 Thing the Biggest Risk for Crocs Stock?
The maker of foam clogs has been a wonderful, if somewhat volatile, investment in recent years. 
Via The Motley Fool
Don't overlook NASDAQ:CROX—it's a hidden gem with strong fundamentals and an attractive price tag.
CROCS INC (NASDAQ:CROX) is an undervalued gem with solid fundamentals. 
Via Chartmill
Amazon, S&P Global And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Topics Stocks
Crocs Stock Is Up 27% This Year and Is Still Incredibly Cheap
This is the shoe that can't be stopped. 
Via The Motley Fool
Breaking Down Crocs: 9 Analysts Share Their Views
 
Via Benzinga
Peering Into Crocs's Recent Short Interest
 
Via Benzinga
Crocs Inc. (NASDAQ: CROX) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The 3 Growth Stocks That Could Make Your February Unforgettable
With our current economy looking to only boom even more, you need to invest in these key growth stocks for high returns in 2024. 
Via InvestorPlace
Topics Economy
The 3 Best Russell 2000 Stocks to Buy in February 2024
The Russell 2000 took a hit in 2023. Many stocks are undervalued, and now is a great time to buy solid companies at a discounted price. 
Via InvestorPlace
Crocs Stock Jumps 12% On Q4 Earnings, Revenue Beat
Crocs reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $2.37 by 8.86%. The company reported quarterly sales of $960 million, beating the analyst consensus... 
Via Benzinga
Crocs (CROX) Q4 2023 Earnings Call Transcript
CROX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Outlook For Crocs
 
Via Benzinga
NASDAQ:CROX is not too expensive for the growth it is showing.
Despite its growth, NASDAQ:CROX remains within the realm of affordability. 
Via Chartmill
How Is The Market Feeling About Crocs?
 
Via Benzinga
Crocs Stock Is Having A Cakewalk: Here's Why
Crocs beats Q4 earnings estimates with revenue growth, driven by strong performance in Crocs brand, and provides upbeat FY24 outlook despite HEYDUDE brand challenges. 
Via Benzinga
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Economic Data Deluge: Analyst Lists 5 Reasons Why 2024 Will Be Another Good Year For Equity Market
The upward momentum appears to be intact despite the inflation-induced weakness seen earlier this year, and futures trading point to a cautious start. 
Via Benzinga
Topics Stocks
Crocs Shuffles Toward Buy Point As HeyDude Raises Q4 Doubts
Crocs stock closes in on a buy point with Q4 earnings due. The clog maker lifted its outlook in January after a disappointing guidance in Q3. 
Via Investor's Business Daily
3 Non-Tech Stocks With Significant Momentum Potential
Undervalued stocks are flying under the radar of investors. As such, we will highlight non-tech stocks with tremendous potential. 
Via InvestorPlace
Nike Is One of the World's Best-Known Brands. But These 3 Shoe Stocks Have Better Growth and Profit Margins.
Nike isn't a bad company. But these other players may be better investments today. 
Via The Motley Fool
Crocs Stock Up 5 Days In A Row, Near Buy Point; Earnings Due
Crocs stock is working on a consolidation with a 110.90 buy point. On Monday Crocs rose 2.36% to a 110.08 close. 
Via Investor's Business Daily
Stocks To Watch This Week - Sunday, Feb. 11
This week, we take a look at small-cap and mid-cap stocks by using ETFs such as MDY and the leveraged ETF TNA. We also like the look of the LABU ETF. 
Via Talk Markets
Topics ETFs
3 Quarterly Releases To Watch Next Week Of February 12
The 2023 Q4 earnings season continues to chug along, with this week’s reporting docket notably busy. And next week, the party continues, with another fresh slate of companies scheduled to unveil... 
Via Talk Markets
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
Via InvestorPlace
Skechers stocks trips on inventory bloat, but there's an upside
Skechers U.S.A. Inc. (NYSE: SKX) is a global lifestyle and performance footwear and apparel company that has really hit its stride in the last decade. 
Via MarketBeat
Topics Economy
NASDAQ:CROX is an undervalued gem with solid fundamentals.
Investors should take notice ofCROCS INC (NASDAQ:CROX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
10 Consumer Discretionary Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.